Saturday , September 18 2021

Tag Archives: lupin

Lupin gains on launching Luforbec 100/6 dose


Lupin is currently trading at Rs. 943.60, up by 4.05 points or 0.43% from its previous closing of Rs. 939.55 on the BSE. The scrip opened at Rs. 952.85 and has touched a high and low of Rs. 952.85 and Rs. 933.75 respectively. So far 40550 shares were traded on ... Read More »

Lupin gets nod from EC for Orphan Drug NaMuscla

Lupin has received approval from European Commission (EC) for NaMuscla (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. Non-dystrophic myotonic disorders are a group of rare, inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. NaMuscla reduces myotonia symptoms in ... Read More »

Lupin’s Nagpur facility receives EIR from USFDA

Lupin has received the Establishment Inspection report (EIR) post the completion of a Pre-Approval Inspection (PAI) for its Phenytoin Sodium Extended Release 100 mg capsules, carried out by The United States Food and Drug Administration (USFDA) at its Nagpur facility in Maharashtra. The inspection conducted in September 2018 concluded without ... Read More »

Lupin reports 42% fall in Q2 consolidated net profit

Lupin has reported results for second quarter ended September 30, 2018. The company has reported a rise of 9.22% in its net profit at Rs 424.75 crore for the quarter under review as compared to Rs 388.90 crore for the same quarter in the previous year. Total income of the ... Read More »

Lupin receives USFDA’s approval for generic Triamcinolone Acetonide Ointment

Lupin has received approval for its Triamcinolone Acetonide Ointment USP, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Mylan Pharmaceuticals, Inc.’s (Mylan) Triamcinolone Acetonide Ointment, 0.1%. Lupin’s Triamcinolone Acetonide Ointment USP, 0.1% is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1%. ... Read More »

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMusclaim (mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults ... Read More »

Lupin’s arm partners with ASHA, NPWH

Lupin’s wholly owned subsidiary in US — Lupin Pharmaceuticals — has partnered with the American Sexual Health Association (ASHA) and the National Association of Nurse Practitioners in Women’s Health (NPWH) to conduct a two-pronged national online survey among women who have been diagnosed with bacterial vaginosis (BV) and healthcare providers ... Read More »

Lupin launches generic Clobetasol Propionate Ointment in US

Lupin has launched Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Clobetasol Propionate Ointment USP 0.05% had annual sales of around $93.4 million in the US (IQVIA MAT June 2018). The company’s Clobetasol Propionate Ointment USP, 0.05% is the ... Read More »

<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'